心脏骤停后治疗性低温:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析纳入9项随机对照试验共4058例心脏骤停后患者,比较治疗性低温与常温治疗。初始可除颤心律患者接受治疗性低温后神经预后显著更好(RR=0.87,95%CI 0.76-0.99,P=0.04),尤其在开始低温较早(<120分钟)和低温持续时间较长(≥24小时)者中;全因死亡率未降低(RR=0.91,95%CI 0.79-1.05);初始不可除颤心律患者无显著神经或生存获益(RR=0.98,95%CI 0.93-1.03;RR=1.00,95%CI 0.95-1.05)。
要点
- 初始可除颤心律患者:治疗性低温组神经预后显著优于常温组(RR=0.87,95%CI 0.76-0.99,P=0.04)。
- 初始可除颤心律患者中,开始低温<120分钟和低温持续≥24小时者神经获益更明显。
- 全因死亡率:治疗性低温组与常温组无显著差异(RR=0.91,95%CI 0.79-1.05)。
- 初始不可除颤心律患者:神经预后(RR=0.98,95%CI 0.93-1.03)与生存(RR=1.00,95%CI 0.95-1.05)均无显著获益。
- 证据确定性为中等,提示治疗性低温对初始可除颤心律患者可能有神经保护作用。
适用人群与场景
- 心脏骤停后患者,纳入比较治疗性低温与常温治疗的随机对照试验。
- 亚组分析按初始心电图心律分为可除颤心律与不可除颤心律。
研究设计与关键结果
- 研究类型:随机对照试验的系统评价与Meta分析,纳入9项RCT共4058例患者。
- 主要终点(神经预后):初始可除颤心律患者治疗性低温组神经预后显著优于常温组(RR=0.87,95%CI 0.76-0.99,P=0.04),尤其在开始低温<120分钟和低温持续≥24小时者中。
- 次要终点(全因死亡率):治疗性低温组死亡率未显著低于常温组(RR=0.91,95%CI 0.79-1.05)。
- 初始不可除颤心律患者:治疗性低温未提供显著神经获益(RR=0.98,95%CI 0.93-1.03)或生存获益(RR=1.00,95%CI 0.95-1.05)。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析。
- 证据确定性:中等。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对初始可除颤心律的心脏骤停后患者,治疗性低温可能改善神经预后,尤其应尽早开始(<120分钟)并维持至少24小时。
- 对初始不可除颤心律患者,治疗性低温未显示显著神经或生存获益。
- 治疗性低温未显著降低全因死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Targeted temperature management (TTM) with therapeutic hypothermia (TH) has been used to improve neurological outcomes in patients after cardiac arrest; however, several trials have reported conflicting results regarding its effectiveness. This systematic review and meta-analysis assessed whether TH was associated with better survival and neurological outcomes after cardiac arrest.
METHOD: We searched online databases for relevant studies published before May 2023. Randomized controlled trials (RCTs) comparing TH and normothermia in post-cardiac-arrest patients were selected. Neurological outcomes and all-cause mortality were assessed as the primary and secondary outcomes, respectively. A subgroup analysis according to initial electrocardiography (ECG) rhythm was performed.
RESULT: Nine RCTs (4058 patients) were included. The neurological prognosis was significantly better in patients with an initial shockable rhythm after cardiac arrest (RR = 0.87, 95% confidence interval [CI] = 0.76-0.99, P = 0.04), especially in those with earlier TH initiation (<120 min) and prolonged TH duration (≥24 h). However, the mortality rate after TH was not lower than that after normothermia (RR = 0.91, 95% CI = 0.79-1.05). In patients with an initial nonshockable rhythm, TH did not provide significantly more neurological or survival benefits (RR = 0.98, 95% CI = 0.93-1.03 and RR = 1.00, 95% CI = 0.95-1.05, respectively).
CONCLUSION: Current evidence with a moderate level of certainty suggests that TH has potential neurological benefits for patients with an initial shockable rhythm after cardiac arrest, especially in those with faster TH initiation and longer TH maintenance.
参考来源
- Chiu PY, Chung CC, Tu YK, et al. Therapeutic hypothermia in patients after cardiac arrest: A systematic review and meta-analysis of randomized controlled trials. Am J Emerg Med. 2023. PMID: 37421815. doi:10.1016/j.ajem.2023.06.040
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。